Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | ICMT | O60725 | 5/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775381 | 0.92 | PPARG (0.44) | MAPTMAPK10ICMTPPARGF10 | |
| SCHEMBL6690152 | 0.91 | KDM4E (0.43) | MAPTMAPK10FABP4ICMTPARP1 | |
| SCHEMBL6693716 | 0.89 | F10 (0.48) | MAPTMAPK10FABP4ICMTPPARG | |
| SCHEMBL6770631 | 0.89 | PLA2G2A (0.46) | FABP4F10PARP1POLBFAAH | |
| SCHEMBL6694433 | 0.89 | PLA2G2A (0.46) | MAPTPARP1POLB | |
| SCHEMBL6898645 | 0.88 | PPARG (0.48) | MAPTMAPK10FABP4PPARGLMNA | |
| SCHEMBL6781985 | 0.87 | MAPT (0.44) | MAPTMAPK10FABP4ICMTPPARG | |
| SCHEMBL6770537 | 0.87 | FABP3 (0.41) | FABP4ICMTF10FEN1LMNA | |
| SCHEMBL7955041 | 0.86 | PLA2G2A (0.49) | FABP4 | |
| SCHEMBL6776332 | 0.86 | MAPT (0.43) | MAPTMAPK10FABP4ICMTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |